瑞普生物(300119) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥533,199,134.68, representing a 20.42% increase compared to ¥442,780,482.14 in the same period last year[5] - Net profit attributable to shareholders was ¥87,571,107.92, an increase of 8.35% from ¥80,823,461.46 in the previous year[5] - The basic earnings per share increased by 9.13% to ¥0.1901 from ¥0.1742 year-on-year[5] - Net profit for Q1 2024 was ¥93,504,682.67, representing a 6.4% increase from ¥87,502,825.62 in Q1 2023[30] - Earnings per share (EPS) for Q1 2024 was ¥0.1901, compared to ¥0.1742 in the previous year, reflecting a growth of 14.0%[31] - The company reported a total comprehensive income of ¥93,504,682.67 for Q1 2024, compared to ¥87,502,825.62 in the same period last year[31] Cash Flow - The net cash flow from operating activities surged by 205.13%, reaching ¥89,135,929.23 compared to ¥29,212,171.85 in the prior year[5] - Cash inflow from operating activities totaled ¥547,363,142.82, an increase from ¥489,240,423.96 in the same quarter last year[33] - The net cash flow from operating activities for Q1 2024 was ¥89,135,929.23, a significant increase from ¥29,212,171.85 in Q1 2023, reflecting a growth of approximately 205%[34] - The company reported a net increase in cash and cash equivalents of ¥279,916,691.96 for Q1 2024, contrasting with a net decrease of ¥54,701,596.71 in Q1 2023[35] - The cash inflow from borrowing activities was ¥204,000,000.00, an increase from ¥125,600,000.00 in the previous year, marking a growth of approximately 62%[34] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,664,480,174.79, a 1.04% increase from ¥6,595,941,501.08 at the end of the previous year[5] - The company's total current assets reached RMB 3.379 billion, compared to RMB 3.263 billion at the beginning of the period, reflecting a growth of approximately 3.54%[25] - The company's total liabilities decreased from RMB 1.791 billion to RMB 1.780 billion, indicating a reduction of about 0.62%[26] - The company's cash and cash equivalents increased to RMB 617.35 million from RMB 335.40 million, representing a growth of approximately 84.06%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,265[12] - The largest shareholder, Li Shoujun, holds 35.92% of the shares, totaling 167,474,479 shares, with 125,605,859 shares pledged[12] - The percentage of shares held by the top ten shareholders accounts for a significant portion of the company's equity, indicating concentrated ownership[12] Research and Development - The company continues to focus on research and development to enhance its product offerings and market position[15] - Research and development expenses amounted to ¥36,418,931.94, up 13.8% from ¥32,060,179.48 in Q1 2023[28] - The company obtained four new veterinary drug registration certificates during the reporting period, enhancing its capabilities in livestock and pet health[15] - The company successfully launched the cat trivalent vaccine "Rui Miao Shu," which is the first domestic vaccine to pass emergency evaluation and obtain a temporary approval number from the Ministry of Agriculture and Rural Affairs[17] - The company signed a cooperation development agreement for the cat HCPC quadrivalent mRNA vaccine with Jiangsu Shenji Biotechnology Co., focusing on developing vaccines for multiple feline diseases[18] Future Plans and Strategies - The company plans to continue expanding its market presence and investing in new product development to drive future growth[5] - The company aims to create maximum value for customers through competitive products and services, reflecting its global vision and industry perspective[15] Financial Adjustments and Compliance - The company announced delays in certain fundraising projects, adjusting the expected completion dates for two projects to December 31, 2024, and December 31, 2026, respectively[21] - The company did not undergo an audit for the Q1 2024 report, as indicated in the financial statements[36] - The company has adopted new accounting standards starting from 2024, which may impact future financial reporting[36]